Our Vision

Whole Person Healing. For All.

Sunstone is redefining what it means to heal by creating a safe and compassionate setting for the delivery of psychedelic-assisted therapy within a medical framework. With a range of clinical trials, a highly-trained interdisciplinary team, and purposely designed centers, we are committed to treating the whole person.

Our Mission

Our mission at Sunstone is to establish the gold standard for psychedelic clinics to deliver care that reduces the emotional suffering of those affected by complex mental health challenges and disorders, and to make safe, effective psychedelic-assisted therapy accessible.

Whole Person Healing is

Our Values

At Sunstone, we see healing as an ongoing journey rather than a destination. Our work is grounded in human-centric care, rigorous medical practice, nuanced therapy, and superior operational standards.

Work and Think with Rigor

Execute with precision and efficiency, informed by critical thinking that understands context, implications, and potential consequences.

Act with Love

Assume the best of people and foster trust, safety, and respect. Take action to build and maintain relationships.

Care for People

Support the betterment of all and cultivate shared belonging by demonstrating inclusion, kindness, compassion, and transparency.

Learn and Grow

Challenge yourself by uncovering biases and blind spots, asking for help, and reflecting on and refining what’s working well and what can be improved.

Innovate Boldly

Lead courageously with new ideas by staying close to curiosity and continuing to evolve through iteration, testing, and improvement.

Our Vision

Sunstone is creating a new model of integrative care with a whole-person approach that is measured and patient-centric. With you as the patient in mind, we are pioneering the delivery of psychedelic-assisted therapies by developing standard-setting experiences, conducting targeted research, training and supporting therapists, and operating best-in-class psychedelic research facilities.

Meet the Team

Sunstone’s team includes oncologists, licensed mental health professionals, researchers, and clinical staff with deep expertise in psychedelic-assisted therapy. With over 100 years of combined experience, we not only deliver exceptional care but also shape national standards in training, certification, and patient care, while contributing to leading institutions and peer-reviewed research.

With care and precision.

Manish Agrawal, M.D.

Chief Executive Officer, Co-Founder

Kim Roddy, MBA

Chief Operating Officer, Co-Founder

Rachel Winzer, M.S.

Therapist Program Director

Leith States, MD MPH MBA FACPM

SVP, Strategic Military Initiatives

Get to Know Us

Meet The Sunstone Team

Expertise Informed by Experience

Sunstone is guided by a team of Clinical Research Coordinators with over 30 years of combined clinical expertise and over 5 years of specialized experience in psychedelic research.

We are currently offering trials to address depression, treatment-resistant depression, cancer and depression, and adjustment disorder. These trials use a variety of psychedelic compounds including, but not limited to psilocybin, MDMA, DMT and analogs.

Explore Open Studies

Adjustment Disorder (AD)
Advanced Illness
Generalized Anxiety Disorder
Major Depressive Disorder (MDD)
Major Depressive Disorder in Patients with Cancer
Post-Traumatic Stress Disorder
Postpartum Depression
Treatment-Resistant Depression

Psilocybin & Analogs
MDMA & Analogs
LSD & Analogs
DMT & Analogs
Methylone & Analogs

AtaiBeckley
Compass Pathways
Gate Neuroscience
Helus Pharma
Resilient Pharmaceuticals
Reunion Neuroscience
Transcend Therapeutics
Usona Institute

Adventist HealthCare
Dana-Farber Cancer Institute
Johns Hopkins Center for Psychedelic &
Consciousness Research
McGill University
Memorial Sloan Kettering Cancer Center
The University of Vermont

Participating in a clinical trial at Sunstone contributes to advancing scientific knowledge in the field of mental health research. Sunstone’s clinical team has authored 13 papers on psychedelic research in leading journals, including Cancer, JAMA Oncology, and NIH-Heals.

View Published Research

Learn More

Apply for a clinical trial at Sunstone Therapies

Sunstone provides access to psychedelic-assisted therapy through FDA-approved clinical trials designed for individuals facing complex mental health challenges. We carefully screen each applicant to determine eligibility based on medical history, diagnosis, and current needs. Those who qualify receive care in a safe, compassionate, and professionally supervised setting.

Apply for a clinical trial